NovaBay Pharmaceuticals Inc NBY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NBY is a good fit for your portfolio.
News
-
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
-
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
-
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
-
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
-
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
-
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
-
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
Trading Information
- Previous Close Price
- $0.08
- Day Range
- $0.07–0.08
- 52-Week Range
- $0.07–1.42
- Bid/Ask
- $0.08 / $0.08
- Market Cap
- $2.78 Mil
- Volume/Avg
- 526,917 / 2.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.02
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 26
- Website
- https://www.novabay.com
Valuation
|
Metric
|
NBY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.64 |
Price/Sales | 0.02 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NBY
|
|---|---|
Quick Ratio | 0.91 |
Current Ratio | 1.67 |
Interest Coverage | — |
Quick Ratio
NBY
Profitability
|
Metric
|
NBY
|
|---|---|
Return on Assets (Normalized) | −51.12% |
Return on Equity (Normalized) | −134.02% |
Return on Invested Capital (Normalized) | −69.06% |
Return on Assets
NBY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fkrvlmrcf | Zmwf | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rdwbwmk | Wqvsxy | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vghtkxvv | Qfflsy | $99.5 Bil | |
MRNA
| Moderna Inc | Gxqswtdz | Mmxy | $38.8 Bil | |
ARGX
| argenx SE ADR | Xsjmjjjd | Pmnf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ddyxncpq | Fhy | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mzvfglvxj | Dlqfmm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Szydpsbdm | Vncxb | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xsdnvwqfn | Tgyty | $12.5 Bil | |
INCY
| Incyte Corp | Fswwkrw | Rrdhn | $11.6 Bil |